Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Medtronic
Dow
Express Scripts
Colorcon

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

ONZETRA XSAIL Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Onzetra Xsail patents expire, and when can generic versions of Onzetra Xsail launch?

Onzetra Xsail is a drug marketed by Currax and is included in one NDA. There are seventeen patents protecting this drug.

This drug has two hundred and fifty-one patent family members in twenty-eight countries.

The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

Drug patent expirations by year for ONZETRA XSAIL
Drug Prices for ONZETRA XSAIL

See drug prices for ONZETRA XSAIL

Recent Clinical Trials for ONZETRA XSAIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Avanir PharmaceuticalsPhase 3

See all ONZETRA XSAIL clinical trials

Recent Litigation for ONZETRA XSAIL

Identify potential future generic entrants

District Court Litigation
Case NameDate
ADAMAS PHARMA, LLC v. SANDOZ INC.2018-05-10

See all ONZETRA XSAIL litigation

Synonyms for ONZETRA XSAIL
(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide
(3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide #
1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide
1-[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]-N-methyl-methanesulfonamide
1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide
103628-46-2
103628-48-4 (succinate)
1H-Indole-5-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-
3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole -5-methanesulphonamide
3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide
3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide
3-[2-(Dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide
628S462
8R78F6L9VO
AB0016356
AB00698285_14
AB00698285_15
AB00698285-12
AB00698285-13
AC1L1K6B
AJ-08373
AKOS015894924
AN-5271
API0004291
AVP 825
AVP-825
AVP825
BCP02237
BDBM50005835
BIDD:GT0248
BRD-K50938287-001-01-7
BRN 6930870
BSPBio_002304
C07319
C14H21N3O2S
CAS-103628-46-2
CCG-230331
CHEBI:10650
CHEMBL128
D00451
DB00669
DSSTox_CID_3628
DSSTox_GSID_23628
DSSTox_RID_77118
DTXSID4023628
FT-0631027
GR 43175
GR 43175X
GR-43175
GTPL54
HMS2231B21
HMS3369A05
HSDB 7742
I06-0076
Imigran (TN)
Imigran Recovery
Imitrex (TN)
Imitrex Oral
Imitrex, Imigran ,Treximet
J-001014
KB-217141
KQKPFRSPSRPDEB-UHFFFAOYSA-N
L000584
LS-83175
MCULE-3991948648
MLS001195659
MLS001304742
MolPort-002-885-863
NCGC00095838-01
NCGC00095838-02
NCGC00095838-03
NCGC00095838-04
O262
SBI-0206837.P001
SC-18016
SCHEMBL1482
SMR000596517
SPECTRUM1505372
STL451003
Sumatran
sumatriptan
Sumatriptan (JAN/USP/INN)
Sumatriptan [USP:INN:BAN]
Sumatriptanum
Sumatriptanum [INN-Latin]
Sumax
Tox21_111528
Tox21_111528_1
UNII-8R78F6L9VO
Zecuity
Zembrace SymTouch
ZINC14360

US Patents and Regulatory Information for ONZETRA XSAIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Moodys
Baxter
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.